Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. (ALDX)

Core Viewpoint - A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for failing to disclose critical information regarding clinical trial results, leading to significant stock price decline and investor harm [1][2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of all individuals or entities that purchased Aldeyra securities between November 3, 2023, and March 16, 2026 [1]. - The complaint alleges that the defendants did not disclose that the results of the reproxalap clinical trials were inconsistent, rendering any positive findings unreliable [2]. Group 2: Impact on Stock Price - Following the revelation of the alleged failures to disclose, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share on March 17, 2026 [3]. Group 3: Investor Actions - Investors who acquired shares of Aldeyra are encouraged to contact the law firm before the lead plaintiff motion deadline on May 29, 2026, to discuss their rights and interests regarding the class action [4].